FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: A recent study in CIDP patients tested an FcRn monoclonal antibody, (IgG4P) rozanolixizumab, which led to > 80% reduction of IgG but failed to meet the primary endpoint, which was changed from baseline to week 13 in inflammatory Rasch-built Overall Disability Scale (iRODS) score [16].